BioVaxys Announces Study On Modified Spike Protein In COVID-19 Vaccine To Reduce Risk Of Rare Side Effects
BioVaxys Technology Corp. (CSE: BIOV) announced this morning that it has initiated a study on the reduced ACE2 binding capabilities
Read moreBioVaxys Technology Corp. (CSE: BIOV) announced this morning that it has initiated a study on the reduced ACE2 binding capabilities
Read moreBioVaxys Technology Corp. (CSE: BIOV) announced this morning that its France-based manufacturing partner, Bio Elpida, has reached milestones in its
Read moreCOVID-19 related stocks are all the rage this morning, however it appears to be for the wrong reason. Following the
Read more